CNS Pharmaceuticals (CNSP) Investor presentation summary

Executive leadership and strategic direction

• Newly assembled executive team brings deep expertise in oncology, neurology, and rare diseases, with proven track records in clinical development and public company transformation.

• Leadership includes specialists in clinical, regulatory, technical, financial, and business development roles, supporting rapid execution and value creation.

• Strategic pivot focuses on acquiring high-value, differentiated assets in oncology or neurology with strong commercial potential.

• Lean operating structure and capital-efficient development are prioritized to maximize value.

Asset acquisition and development strategy

• Formal asset search targets preclinical and clinical-stage programs with strong biological rationale and near-term catalysts.

• Focus on acquiring underfunded, shelved, or distressed assets in oncology or neurology, leveraging favorable market conditions.

• Clear selection criteria include scientific validation, defined regulatory strategy, and commercial opportunity.

• Goal to deliver a meaningful clinical or regulatory milestone within 12 months of acquisition.

Financial position and capital structure

• Secured $22.5 million in financing from leading healthcare investors, enabling the strategic pivot and asset acquisitions.

• May 2026 private placement resulted in a pro forma fully diluted market capitalization of approximately $54.6 million.

• Clean capital structure with no debt, preferred, or convertible securities; restrictions on additional equity issuance for one year.

• Warrant exercises are subject to beneficial ownership caps to maintain shareholder alignment.